We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

15 hedge funds and large institutions have $1.01M invested in Theriva Biologics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more capital invested

Capital invested by funds: $725K → $1.01M (+$283K)

0% more ownership

Funds ownership: 0.26% → 0.27% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

12% less funds holding

Funds holding: 17 → 15 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$4.17K
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.82K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$14.4K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$7.46K
3
Northern Trust
Northern Trust
Illinois
-$6.41K
4
Bank of America
Bank of America
North Carolina
-$18
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$525K – – –
BlackRock
2
BlackRock
New York
$190K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$116K – – –
State Street
4
State Street
Massachusetts
$48.7K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$39K +$2.82K +160 +12%
BCM
6
Bridgeway Capital Management
Texas
$28.5K – – –
Northern Trust
7
Northern Trust
Illinois
$26.6K -$6.41K -364 -25%
Charles Schwab
8
Charles Schwab
California
$13.6K – – –
Fisher Asset Management
9
Fisher Asset Management
Washington
$12.6K – – –
UBS Group
10
UBS Group
Switzerland
$5.93K +$4.17K +237 New
IA
11
IFP Advisors
Florida
$382 – – –
TRCT
12
Tower Research Capital (TRC)
New York
$145 – – –
Wells Fargo
13
Wells Fargo
California
$109 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$47 – – –
SPIA
15
Steward Partners Investment Advisory
New York
$14 – – –
Morgan Stanley
16
Morgan Stanley
New York
$12 – – –
Bank of America
17
Bank of America
North Carolina
$6 -$18 -1 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$14.4K -824 Closed
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$7.46K -427 Closed

TOVX Hedge Fund Activity: Q2 2023 in Review

15 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2023, worth a combined $1.01M — up 39% from $725K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TOVX and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, opening a new position worth an estimated $4.17K. The largest seller was Citadel Advisors, exiting entirely with an estimated $14.4K sold.

  • 15 institutional investors held Theriva Biologics (TOVX) as of Q2 2023, down from 17 in Q1 2023.
  • Funds reported $1.01M of Theriva Biologics stock for Q2 2023, up 39% quarter-over-quarter.
  • 1 fund opened new Theriva Biologics positions in Q2 2023 and 3 closed out, a net change of -2 holders.
  • The largest Theriva Biologics buyer in Q2 2023 was UBS Group, an estimated $4.17K added.
  • The largest Theriva Biologics seller in Q2 2023 was Citadel Advisors, an estimated $14.4K sold.

Based on aggregated 13F filings for Q2 2023.